Biotech

Pharma M&A avalanche accelerates into mega-cap territory

The biopharma M&A machine hit a record $34.4B in Q2 2026 exit value, and July shows no sign of deceleration. AbbVie's $10.9B acquisition of Apogee Therapeutics, GSK's $10.6B takeout of Nuvalent at a 40% premium, Curium's $7B buyout of Lantheus, J&J's $785M pick-up of Sail Biomedicines, and Eli Lilly's ~$7B acquisition of Kelonia Therapeutics collectively signal that large pharma is aggressively buying clinical-stage assets rather than building organically. UCB's competitive outbid for Candid Therapeutics (which had $370M in prior venture backing) further underscores that auction dynamics are intensifying across autoimmune, oncology, and radiopharmaceutical franchises.

The $3.8B valuation placed on an AI biology platform via a $400M Series B/C — backed by Sequoia, Kleiner Perkins, General Catalyst, Thrive Capital, Index Ventures, and even OpenAI — marks a step-change in how the market prices generative AI applied to proteins and drug design. This follows the same capital behavior seen in Lila Sciences and EvolutionaryScale: frontier model architecture is being treated as a therapeutics platform, not merely a tool. New Limit, Converge Bio, Profluent, and Cradle each represent a different layer of the stack — from longevity epigenomics to sequence-generative design — all attracting institutional backing at steep step-ups.

Why it matters · Investors pricing AI biology platforms at $3B+ valuations at Series B signal a winner-take-most dynamic is forming; operators and founders must now compete on foundation-model depth, not just application surface.

Kailera Therapeutics (obesity, $625M IPO), Odyssey Therapeutics ($304M Nasdaq IPO), Avalyn Pharma ($300M IPO at $813M valuation), and Hemab Therapeutics ($301.5M IPO) all priced successfully in the same window, confirming the public markets remain receptive to clinical-stage biotech with differentiated mechanisms. Parabilis Medicines also filed in Q2. The $4.6B IPO signal in late July suggests at least one additional large-cap debut is imminent.

Why it matters · A durable IPO window means founders and late-stage investors have a credible dual-track optionality — IPO or strategic M&A — compressing the risk premium on growth-stage rounds.

Colossal Biosciences is seeking to raise at a $20–30B valuation — up from $10.2B just 18 months ago — on the strength of its de-extinction narrative and a pivot to revenue-generating status; investors explicitly cite pharmaceutical, climate, and longevity applications. Calico and Revel Pharma's published AlphaFold-designed enzyme, which cleared 55% of glycation age markers to revert elderly skin to a biological age of 31, adds scientific credibility to longevity's investability thesis. New Limit, co-founded by Coinbase's Brian Armstrong with Eli Lilly Ventures participating, further institutionalizes the space.

Why it matters · Longevity and de-extinction are crossing from curiosity to institutional asset class, and early movers with platform IP will set valuation anchors that cascade into adjacent aging-biology startups.

Series B leads all stages with 25 deals and $13.1B deployed over the past 90 days — more than four times the capital of Series C (9 deals, $3.1B) and nearly eight times Series A ($1.7B). The $3.05B Series B signal from late July alone represents nearly a quarter of all 28-day capital. This concentration reflects a barbell: tiny pre-seed bets (2 deals, $3M) on AI-biology moonshots, then a massive aggregation of conviction at Series B where clinical proof-of-concept meets scalable platform.

Why it matters · Capital allocators benchmarking against the stage mix should overweight Series B entry points in AI-native and clinical-stage biotech, where the data shows the deepest institutional consensus and largest absolute dollars.